BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 2, 2019
View Archived Issues
Umbralisib plus ibrutinib demonstrate safety and activity in patients with leukemia and lymphoma
Read More
Methylscape alteration of DNA physicochemical properties can be applied for cancer diagnostic assays
Read More
Discovery of osimertinib analogue that selectively inhibits EGFR for NSCLC treatment
Read More
Novel selective azaindole TGF-beta receptor kinase inhibitors may improve immuno-oncology therapy
Read More
AOH-1160 demonstrates promising anticancer activity without significant toxicity in vivo
Read More
Sleeping sickness parasite can make its own sugar
Read More
Genetic diversity makes for better Alzheimer's model
Read More
ST-8116 demonstrates promising antitumor activity in preclinical models of colon cancer
Read More
Epigenetic analysis boosts malaria pathogenesis understanding
Read More
Patient enrollment ongoing in phase I study of BOS-172738
Read More
NicOx presents new compounds for eye disorders
Read More
Chiesi Farmaceutici patents new MAPK 14 inhibitors
Read More
Cadila Healthcare synthesizes NLRP3 inhibitors
Read More
Hanmi Science describes KDM1A inhibitors
Read More
Dosing begins in phase III study of Tyvyt for first-line esophageal squamous cell carcinoma
Read More
New PDE9 inhibitors presented by Merck & Co.
Read More
ALCAM-EGFR axis discovered as therapeutic target in multiple myeloma
Read More
BioCryst doses first patient in phase I trial of intravenous galidesivir
Read More
Cybrexa selects CBX-11 as lead clinical development candidate
Read More
Arcturus Therapeutics nominates ARCT-810 as development candidate for OTC deficiency
Read More